We found that ABCA7 VNTR expansion carriers have decreased levels of Aβ1–42, reduced Aβ1–40, sAPPα, sAPPβ, and YKL-40 levels compared with non-carrier AD patients. This evidence concerns the gene ABCA7 and Alzheimer disease.